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Therapeutic proteins/peptides are mostly administered as parenteral (injectable) preparations as a 
result of their poor oral bioavailability which is due to degradation by proteolytic enzymes, poor 
membrane permeability and large molecular size. However, the oral route would be preferred to the 
parenteral administration because it is more convenient for self-administration, non-invasive and more 
patient friendly. Consequently, efforts have intensified over the past two decades to maximize the 
extent of absorption of protein and peptide drugs in order to achieve optimum bioavailability via the 
oral route. A suitable oral delivery system should retain the drug and maintain its integrity until it gets 
to the region of maximum absorption where the protein/peptide is released. It would be advantageous 
for such a delivery system to be capable of attaching itself to the absorptive cells in that region during 
the course of drug release by means of specific interactions with the tissue components. Furthermore, 
movement of drug should be independent of prevailing factors in the gut during passage. This review 
examines the various efforts and strategies that have been used to pursue the goals of effective oral 
peptide delivery, progress made so far, as well as current trends and future prospects. Relevant issues 
and phenomena such as membrane permeability control, intestinal absorption, paracellular pathway 
and targeting have also been discussed.  
 





Over the last two decades, the field of biomedical 
research has witnessed dramatic advances in the 
understanding, diagnosis, and treatment of human 
diseases. These developments have been fueled by an 
increased awareness of the essential roles played by 
endogenous proteins and peptides in the regulation and 
integration of life processes (Samonen, 1985). For 
example, in the form of skin, hair, cartilage and muscle, 
proteins hold together, protect, and provide structure to 
the body of a multicellular organism. In the form of 
enzymes, hormones, antibodies and globulins, they 
catalyze, regulate and protect the body chemistry while  
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in the form of haemoglobin, myoglobin and various 
lipoproteins, they effect the transport of oxygen and other 
chemical substances within the body (Schwendeman et 
al., 1996; Adessi and Sotto., 2002). The increasing 
importance of proteins and peptides can be attributed to 
three main developments. First, improved analytical 
methods have fostered the discovery of numerous 
hormones and peptides that have found applications as 
biopharmaceuticals. Second, molecular biology and 
genetic engineering have enabled the large-scale 
production of polypeptides previously available only in 
small quantities. Third, there is now a better 
understanding of the role of regulatory proteins/peptides 
in the pathophysiology of human diseases. 
Consequently, pharmaceutical scientists are now 
routinely using specific peptide sequences as lead 
structures for drug development. (Adessi and Sotto, 
2002, 2004). 
 




Despite the high level of activity in peptide-based drug 
research, several obstacles hinder the development of 
peptides into useful therapeutically deliverable agents, 
the most important of which is imparting good 
bioavailability while maintaining pharmacological efficacy 
(Humphrey and Ringrose, 1986). This problem stems 
from the unique structural features of peptides which are 
directly linked to their high instability in biological milieu, 
rapid elimination from plasma, poor transportability 
across membranes and ease of metabolism either within 
the gastrointestinal tract or within the cells lining the tract 
(Davis et al., 1986; Schwendeman et al, 1996). 
 
 
ORAL DELIVERY OF PROTEINS AND PEPTIDES 
 
A primary objective of oral delivery systems is to protect 
protein and peptide drugs from acid and luminal 
proteases in the GIT. More recent efforts seem to focus 
on site-specific delivery systems. The site could be an 
organ, a cell subset or even an intracellular region with 
the objective of restricting the distribution of the peptide 
to the specific target site. This should allow for an 
increase in efficacy with an attendant decrease in toxicity 
(Arhewoh and Okhamafe, 2004). 
Various systems for achieving site-specific delivery of 
orally administered protein/peptide drugs have been 
addressed in recent years including coating systems 
based on pH changes and enzymatic activity of intestinal 
microflora (Macloid et al., 1999; Stubbe et al., 2001), 
nanoparticles, (Shinji et al., 1997), liposomes (Kimura 
and Saishin, 1985), matrix devices (Krishnaiah et al., 
2001) and conjugate (degradable prodrug) formation 
(Yano et al., 2002; Arhewoh and Okhamafe, 2004). All of 
these have produced variable release profiles, often 
because the transit time through the colon can vary 
substantially from as low as 6 to as high as 30 h. Several 
of these approaches are somewhat complex and if they 
were to be translated into actual manufacture of oral 
delivery systems, the products would be expensive and, 
therefore, unaffordable in most developing countries. In 
our laboratories, preliminary studies on microcapsules of 
chitosan-alginate modified with selected excepients such 
as HPMCAS, talc, microcrystalline cellulose, polymeta-
crylates and pectins were carried out. Protein release 
was determined at different pH media spanning the pH 
range of the gut (Figure 1). It was observed that 
microcapsules modified with talc and microcrystalline 
cellulose had higher protein retention in the core in all the 
pH tested (Okhamafe et al., 1996; Ahonkhai et al., 2005; 
Arhewoh et al., 2005). This shows that modification of the 
core of chitosan-alginate microcapsules could facilitate 
drug targeting to the colon. 
 
 
ORAL GENE DELIVERY 
 
In vivo production of proteins through oral gene therapy 





Rather than administering the protein itself, the DNA 
plasmid that codes for it is swallowed. This then attaches 
to the cells in the small intestine where it manufactures 
the required protein drug using available materials in the 
cell. The protein is thereafter absorbed into the blood 
stream. The gene has a short half-life and hence must be 
administered regularly to be effective. The advantage is 
that it provides for safe, easily managed treatment unlike 
most gene-based therapies currently available. It is also 
hoped that this system will be relatively free from ectopic 
expressions usually experienced with gene therapies 
since the bulk of the administered genes remain within 
the intestine and is passed out with feaces along with 
sloughed cells of the intestinal epithelium. 
 
 
MEMBRANE PERMEABILITY CONTROL  
 
It is important that a successful oral delivery system 
incorporating a membrane would exhibit a permeability, 
which can be modulated controlled by factors favourable 
to the targeting of the drug to the specific site of 
absorption. To achieve this, suitable polymer additives 
may be used. The benefits of this approach have been 
highlighted by Okhamafe and Goosen (1993). Membrane 
permeability control is also a critical factor in living cell 
encapsulation technology and in the development of 
bioartificial organs. Furthermore, membrane modulation 
is often employed to improve the strength and stability of 
the microcapsule itself (Okhamafe and Goosen, 1999). 
Ahonkhai et al. (2005) recently found that by 
incorporating polymers or solid fillers in the core of 
chitosan-alginate microcapsule, the release of a model 
protein, bovine serum albumin (BSA) can be modulated 
such that 70% of the protein is delivered to the desired 
absorption site in the gut 9 h later (see Figure 1). Related 
applications include the pre-purification and concentration 
of products of cell encapsulation, release into the 
circulatory system of hormonal and enzymatic products 
generated by bioartificial organs which are protected from 
components of the immune system, principally 
immunoglobulins. Some relevant parameters to be 
considered in membrane permeability control are 







The primary function of the intestine is the digestion and 
absorption of food substances including proteins. Within 
the intestinal lumen, pancreatic endopeptidases chiefly 
trypsin, elastase and chymotrypsin together with the 
exopeptidases, carboxyl peptidase A and B, produce 
amino acids and peptides typically 2 to 6 residues in 
length.  The efficient absorption of an intact peptide, 
therefore, is the exception rather than the rule.  Examples   
 




Table 1. Critical factors affecting microcapsule membrane permeability. 
 
Capsule wall Solute Capsule Process factor 














































Figure 1. Protein (BSA) release at pH 1.2 from microcapsules modified with different additives – Talc 
(T), Eudragit L100 (L), Eudragit RSPM (RS), HPMCAS (H), microcrystalline cellulose (M) and Control 
(i.e., unmodified) (C) 
 
 
orally absorbed, biologically active peptides are rare.  
However, both thyrotrophin-releasing hormone (TRH) 
(Yokohama et al., 1984) and the luteinizing hormone-
releasing hormone (LHRH) analogue, leuprolide 
(Gonzalez-Barcena et al., 1975) were reported to exert 
biological activity when given orally in rat and man. The 
activity of these two proteins is a reflection of their 
extreme potency as only a small portion of TRH was 
actually absorbed in rat and man. It was further observed 
that in the rat, absorption is limited to the upper region of 
the intestine and is mediated by a Na+ dependent, 
peptide transport system (Yokohama et al., 1984). 
Remarkably, absorption of DN-1417, a close structural 
analog of TRH, is not active, but occurs by passive 
diffusion in all parts of the intestine.  Furthermore, only 
1% is absorbed in rat and 10% in dog. This example 
illustrates the sensitivity of transport proteins to structural 





Most of the water and electrolytes in chyme, which pass 
through the ileocecal valve into the large intestine, are 
absorbed in the colon, usually leaving less than 100 ml of 
fluid to be excreted in the feces. Most of the absorption in 
the large intestine occurs in the proximal one half of the 
colon, giving this portion the name, absorbing colon. The 
mucosa of the large intestine, like that of the small 
intestine, has a high capability for active absorption of 
sodium (Guyton and Hall, 1996). Numerous bacteria, 
especially colon bacilli, are present normally in the 
absorbing colon (Wilson and Basit, 2005). They are 
capable of digesting small amounts of cellulose, in this 
way providing a few calories of nutrition to the body each 
day. Substances formed as a result of bacterial activity 
are vitamin K, vitamin B12, thiamin, riboflavin and various 
gases that contribute to flatus in the colon, especially 
carbon dioxide, hydrogen and methane. It is based on 
this bacterial activity that the colon can be used as a site 
of drug delivery whereby polymer-coated drugs are 
targeted to the colon. The bacteria in the colon degrade 
the polymer thus releasing the drug where it can either 
exert local action or be absorbed into systemic circulation 
(Stubbe at al., 2001; Wilson and Basit, 2005). 
Colonic transit is an important factor in the absorption 
of  drugs  that  either  act  locally   in   the   colon   or   are  
 




absorbed into systemic circulation from the colon. The 
time at which a delivery system arrives at the colon 
depends mainly on the gastric emptying rate (Davies et 
al., 1991). The arrival time for a tablet or capsule in the 
colon can range from about 5 h in the fasted condition to 
13 h or longer in the fed condition. In healthy volunteers, 
the colonic transit of tablet or capsules releasing drug 
over a prolonged period probably delivers most of its 
active ingredients to the colon rather than to the upper GI 





Drugs administered through the gastro-intestinal tract are 
normally transported into systemic circulation via the 
portal vein.  As a consequence, compounds can 
sometimes undergo extensive metabolism during the first 
pass through the liver.  Some well-known drugs, such as 
lignocaine, are almost totally metabolized by this process 
with a consequence that little or none is available to the 
general circulation. Other routes, such as rectal, buccal, 
nasal and transdermal, avoid the first pass effect but do 
not provide the convenience of oral delivery. If a drug is 
absorbed through the lymphatic system rather than by 
the portal circulation, it will find its way into the blood via 
the thoracic duct and will, therefore, avoid the first pass 
effect. A drug absorbed lymphatically is incorporated into 
chylomicrons (and other lipoproteins) produced by the fat 
digestion process. Various surfactant solubilised systems 
and other enhancing agents would appear to direct drugs 
to the lymphatic route and there are even claims that 
particulates can be taken up this way (Leferve and Joel., 
1977; Khoo et al., 2001). 
The conjugation of large molecular weight drugs with 
polymers, such as dextran, appears to be an interesting 
strategy for enhancing the lymphatic uptake of anticancer 
agents (Muranishi et al., 1987).  In this case the 
lymphatics could well be the target site (e.g., for 
treatment of metastatic spread) rather than the systemic 
circulation and beyond.  
 
 
PATHWAY FOR PROTEIN/PEPTIDE ABSORPTION 
 
Identifying a region in the intestine that favours 
protein/peptide absorption is a crucial step in the design 
of oral delivery systems for protein drugs. The intestinal 
barrier is of major importance. Furthermore, regional 
variations in the penetration barriers to peptides may 
result in regional differences in their absorption (Kompella 
and Lee, 2001). There are certain factors that affect the 
permeability of molecules through the intestinal barrier 
and these include: 
 
Physicochemical properties of the drug molecules 
Characteristics of the intestinal barrier 
Transport mechanism 






Targeting the drug to specific cells along the lining of 
the intestine may be useful in facilitating protein/peptide 
absorption, for instance, M-cells located on the dome 
epithelium of gut-associated lymphoid tissues are known 
to be capable of sampling macromolecular antigen from 
the lumen through an endocytic pathway (Keljo and 
Hamilton, 1983; Kompella and Lee, 2001). The M-cells 
are located on Peyer’s patches and the possibility of 
administering microparticles orally to target this site has 
been suggested (Eldridge et al., 1990). The researchers 
administered 20 mg of microspheres containing the 
fluorescent dye, coumarin-6 to non-anesthesized mice. At 
48 h, the mice were killed and three representative 
Peyer’s patches, together with the first mesenteric lymph 
node proximal to the appendix and spleen, were excised 
for microscopic observation. The number of absorbed 
microspheres was counted in frozen sections using a 
florescence microscope. The percentage of ingested 
dose was not determined; however, of the microspheres 
investigated, only those composed of polystyrene, poly 
(methylmethacrylate), poly ( hydroxylbutyrate), poly (D, L-
lactide), poly (L-lactide) and poly (D, L-lactide-
coglycolides) were absorbed into the Peyer’s patches of 
the small intestine, while those composed of ethyl 
cellulose, cellulose acetate hydrogen phthalate and 
cellulose triacetate were not. Microsphere uptake 
occurred only in Peyer’s patches and was restricted to 
those microspheres up to 10 µm in diameter. Absorptive 
cells located on the ideal epithelium are known to be 
capable of sampling luminal peptide growth factors 
(Gonnela et al., 1987) bile acids (Ho, 1987) and 
cyanocobalamine (Doscherholmen et al., 1971) 
From recent advances in protein absorption studies 
have emerged a new system termed ‘Active Peptide 
Transport’ (APT) (Stevenson and Keon, 1998). APT 
describes a new formulation that is designed to “actively” 
open alternative absorptive pathways in the body. These 
alternative pathways make transporting proteins to body 
cells and the muscles faster and more efficient. APT is 
important because it is designed to allow the body to 
absorb peptides faster and more efficiently. The body has 
three different protein transport systems that it uses for  
muscle growth. The first system uses free-form amino 
acids. This is a very inefficient system because the free-
form amino acids must compete with one another for 
absorption. The second system involves small, short 
peptide chains of 2 to 3 amino acids linked together. 
These are called di- and tri-peptides. Di- and tri-peptides 
are absorbed into the blood stream through the 
transcellular pathways. The  third  system  involves  large  
molecular weight peptides and is unique to whey protein. 
This is not used when casein, egg white or soy proteins 
are digested. It should be noted that not all proteins 
stimulate all three protein transport systems. In fact, only 
specially made designer proteins stimulate the pathways. 






facilitate the stimulation of all three transport systems and 
can only be found in designer protein. These APT full 
spectrum whey peptides are a complete spectrum of very 






The paracellular pathway is found along the intestinal 
wall and is used by the second and third transport 
systems as an alternative pathway for peptide absorption. 
This pathway is normally closed off to entry of peptides 
and nutrients by a special cell called “tight junction” 
(Stevenson and Koan 1998). In a current model of a tight 
junction, two major integral membrane proteins are found 
- occludin and claudin - each with four membrane 
spanning alpha-helices. The junction depends upon extra  
cellular calcium to maintain integrity. The permeability 
properties of tight junctions vary considerably in different 
epithelia and epithelial cells can transiently alter their tight 
junctions in order to allow increased flow of solutes and 
water through breaches in the junction barriers 
(doscherholmen et al., 1971; Fanning et al., 1998). The 
tight junctions usually prevent the transport of protein 
through the paracellular pathway. However, research has 
shown that specific amounts of key ingredients, the same 
ingredients found in designer protein’s APT, help the tight 
junctions to open (Fanning et al., 1998). Naturally, with 
both the transcellular and paracellular pathways opened, 
protein is potentially absorbed faster and in greater 
amounts. Furthermore, unique protein with molecular 
weight larger than the di- or tri-peptides absorbed by the 
second transport system may be able to pass through 
intact (Stevenson and Koan, 1998; Muranishi and 





Existing methods for selective targeting are based on 
chemical conjugation of therapeutic and diagnostic 
agents or their carriers to cell specific targeting molecules 
(Gaidamakova et al., 2001; Pastorino et al., 2001). These 
methods are limited by potential damage to targeting 
molecules that can be inflicted by the conjugation 
procedure. In addition, conjugation procedures have to 
be developed on case - by - case basis (Amidon, 1995).     
In order to avoid this problem, a new approach has been 
developed to constructing molecular vehicles for target-
mediated delivery of therapeutics and diagnostic agents. 
In this approach, the targeting molecule is expressed as 
a fusion protein containing a recognition tag. The 
recognition tag is defined as a protein or peptide that can 
bind non-covalently with another peptide or protein 
(adapter). In turn, the adapter is chemically conjugated to 
a carrier of therapeutics  or  diagnostics.  The  assembled  




molecular delivery vehicle contains a carrier - adapter 
conjugate, which bound non-covalently to a recognition 
tag fused to the targeting protein (Gaidamakova et al., 
2001).  
Another approach towards delivering drugs into cells is 
the concept of loligomers. Loligomers are synthetic 
peptides composed of a branched polylysine case 
harboring identical arms, each carrying peptide signals 
guiding their import and localization into cells. The most 
important advantages of loligomers include: 
The multivalent presentation of targeting signals 
resulting from a tentacular arrangement. Multivalency 
increases the efficiency of import and intracellular routing 
signals as compared to similar linear peptides. 
Another advantage is that it reduces and delays the 
impact of peptide degradation in terms of cellular 
processing and compartmentalization (Borkx et al., 
2002).  
The vectorial delivery of nucleus – directed loligomers 
into cells has recently been confirmed by microscopy and 
flow cytometry studies (Borkx et al., 2002). Practical uses 
of loligomers include photosenstizers for use in 
photodynamic therapy and the incorporation of cytotoxin 
T-lymphocyte epitopes with a view to creating synthetic 
vaccines. Branched peptide such as loligomers 
represents simple and versatile molecular vehicles with 




Delivery to cancer cells 
 
Cancer treatment has always posed a problem. The 
effectiveness of conventional solid tumor treatment is 
limited by the systemic toxicity and lack of specificity of 
chemotherapeutic agents. Barriers are also frequently 
hampering targeting of drugs and toxins to solid tumors 
and their microenvironment. Present treatment modalities 
are frequently insufficient to eliminate viable cancer cells 
without exceeding the limits of toxicity to normal tissue. 
The coming generation of cancer therapeutics depends 
on the precise targeting and sustained release of anti-
tumor agents to overcome their limitations.  
Phage-derived peptides for targeting of doxorubicin 
conjugates to solid tumors have been designed 
(Schatzlein et al., 2001). Nano-conjugates are low 
molecular weight conjugates of a small drug or toxin and 
a targeting ligand coupled through a cleavable linker 
group. They offer potential advantages for tumor specific 
delivery in diffusion – limited situations. As a model, a  
doxorubicin conjugate targeted to the transferring 
receptor (TFR) was chosen. A library of phage 
expressing a cyclic nanopeptide was panned against 
TFR. The apparent affinity of phages determined by 
surface plasmon resonance (SPR) increased with each 
cycle of the panning procedure. After five rounds, 
approximately   80%   of   phages   expressed   the  same  
 




peptide, which mediated a 30 to 50-fold increased 
receptor specific cellular uptake of the phages. The 
corresponding   peptide   was   synthesized   using   solid  
phage peptide chemistry on a sulphonamide based 
safety catch resin. Crude mixtures of the peptide, as well 
as transferrin itself, were able to inhibit the phage uptake 
significantly.  
Chitosan nanoparticles encapsulating dextran – 
doxorubicin conjugate has been used as carrier for 
targeting tumors (Mitra, 2001). Doxorubicin (DXR) 
commonly used in cancer therapy is known to produce 
undesirable side effects such as cardiotoxicity. To 
minimize these, attempts were made to couple the drug 
with dextran (DEX) and then to encapsulate this drug 
conjugate in hydrogel nanoparticles. By encapsulation of 
the drug conjugate in biodegradable, biocompatible long 
circulating hydrogel nanoparticles, it further improved the 
therapeutic efficacy of the conjugate.  The  size  of  these  
nanopaticles, as determined by quasi-elastic light 
scattering, was found to be 100 ± 10 nm in diameter, 
which favours the enhanced permeability and retention 
(EPR) effect as observed in most solid tumors.        The 
anti tumor effect of these DEX – DXR nanoparticles, was 
evaluated in macrophage tumor cells implanted in Balb/c 
mice. The in vivo efficacy of these nanoparticles as 
antitumor drug carriers was determined by tumor 
regression and increased survival time as compared to 
drug conjugate and free drug. These results suggest that 
encapsulation of the conjugate in nanoparticles not only 
reduces side effects, but also improves its therapeutic 
efficacy in the treatment of solid tumor. Preliminary 
studies to evaluate the potentials of chitosan particles as 
carriers for  doxorubicin was also carried out and it was 
concluded that it was feasible for the chitosan 
nanoparticles to entrap the basic drug, doxorubicin, and 
to deliver it into the cell in its active form (Janes et al., 
2001). 
Water-soluble polymers have been used to target 
tumors. The rationale for the use of water soluble 
polymers for anticancer drug delivery includes the 
potential to overcome some forms of anti-drug resistance 
and preferential accumulation in tumors due to enhanced 
permeability and retention (EPR) effect, biorecognizability 





Several sites in the GIT have been investigated by 
researchers for oral delivery of therapeutic proteins and 
peptide drugs but no major breakthrough with broad 
applicability to diverse proteins and peptides has been 
achieved. Nonetheless, the oral route has distinct 
advantages over the parenteral route which is invasive 
and inconvenient for repeated use. Delivery systems for 
oral administration of therapeutic substances have been 
developed for site-specific delivery in GIT region. Of 





of peptide drugs because of slow transit, low volume and 
a lack of vigorous stirring, leading to an ability to create 
local conditions favourable to stabilization and absorption 
enhancement. In addition, the colonic region has a high 
presence of microbial anaerobic organisms providing 
reducing conditions and sufficient area to partially 
compensate for low peptide mucosal permeability and a 
lack of digestive enzymes (proteases). 
It is expected that in the foreseeable future more focus 
will be on the colon as a region for site-specific delivery of 
therapeutic substances (proteins, peptides, genes, etc) 
that are unstable in the other regions of the GIT in order 
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